Home
/
BioXcel Therapeutics, Inc.
/
Financials
/
Quarterly
BioXcel Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that BioXcel Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2018
Sep 30, 2018
$0
Nov 9, 2018
Q2
2018
Jun 30, 2018
$0
Aug 8, 2018
Q1
2018
Mar 31, 2018
$0
May 14, 2018
Q3
2018
Sep 30, 2017
$0
Nov 9, 2018
Q2
2018
Jun 30, 2017
$0
Aug 8, 2018
Q1
2018
Mar 31, 2017
$0
May 14, 2018
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$98.0K
Nov 12, 2025
Q2
2025
Jun 30, 2025
$120.0K
Aug 12, 2025
Q1
2025
Mar 31, 2025
$168.0K
May 12, 2025
Q3
2025
Sep 30, 2024
$214.0K
Nov 12, 2025
Q2
2025
Jun 30, 2024
$1.10M
Aug 12, 2025
Q1
2025
Mar 31, 2024
$582.0K
May 12, 2025
Q3
2024
Sep 30, 2023
$341.0K
Nov 14, 2024
Q2
2024
Jun 30, 2023
$457.0K
Aug 6, 2024
Q1
2024
Mar 31, 2023
$206.0K
May 9, 2024
Q3
2023
Sep 30, 2022
$137.0K
Nov 14, 2023
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($30.91M)
Nov 12, 2025
Q2
2025
Jun 30, 2025
($19.19M)
Aug 12, 2025
Q3
2025
Jun 30, 2025
($19.19M)
Nov 12, 2025
Q2
2025
Mar 31, 2025
($7.25M)
Aug 12, 2025
Q1
2025
Mar 31, 2025
($7.25M)
May 12, 2025
Q3
2025
Mar 31, 2025
($7.25M)
Nov 12, 2025
Q3
2025
Sep 30, 2024
($13.65M)
Nov 12, 2025
Q2
2025
Jun 30, 2024
($8.30M)
Aug 12, 2025
Q3
2025
Jun 30, 2024
($8.30M)
Nov 12, 2025
Q1
2025
Mar 31, 2024
($26.79M)
May 12, 2025
Q3
2025
Mar 31, 2024
($26.79M)
Nov 12, 2025
Q2
2025
Mar 31, 2024
($26.79M)
Aug 12, 2025
Q3
2024
Sep 30, 2023
($50.49M)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($53.52M)
Aug 6, 2024
Q3
2024
Jun 30, 2023
($53.52M)
Nov 14, 2024
Q3
2024
Mar 31, 2023
($52.80M)
Nov 14, 2024
Q2
2024
Mar 31, 2023
($52.80M)
Aug 6, 2024
Q1
2024
Mar 31, 2023
($52.80M)
May 9, 2024
Q3
2023
Sep 30, 2022
($41.81M)
Nov 14, 2023
Q2
2023
Jun 30, 2022
($37.67M)
Aug 14, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($14.23M)
Nov 12, 2025
Q2
2025
Jun 30, 2025
($15.85M)
Aug 12, 2025
Q1
2025
Mar 31, 2025
($10.10M)
May 12, 2025
Q3
2025
Sep 30, 2024
($15.29M)
Nov 12, 2025
Q2
2025
Jun 30, 2024
($17.30M)
Aug 12, 2025
Q1
2025
Mar 31, 2024
($24.16M)
May 12, 2025
Q3
2024
Sep 30, 2023
($48.30M)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($52.41M)
Aug 6, 2024
Q1
2024
Mar 31, 2023
($51.20M)
May 9, 2024
Q3
2023
Sep 30, 2022
($38.99M)
Nov 14, 2023
Q2
2023
Jun 30, 2022
($36.29M)
Aug 14, 2023
Q1
2023
Mar 31, 2022
($31.48M)
May 9, 2023
Q3
2022
Sep 30, 2021
($26.81M)
Nov 14, 2022
Q2
2022
Jun 30, 2021
($27.61M)
Aug 11, 2022
Q1
2022
Mar 31, 2021
($26.38M)
May 9, 2022
Q3
2021
Sep 30, 2020
($24.77M)
Nov 10, 2021
Q2
2021
Jun 30, 2020
($21.44M)
Aug 10, 2021
Q1
2021
Mar 31, 2020
($15.00M)
May 10, 2021
Q3
2020
Sep 30, 2019
($9.13M)
Nov 12, 2020
Q2
2020
Jun 30, 2019
($8.64M)
Aug 14, 2020